Rhelion Life Sciences Corp. engages in the research and development of psychedelic drug in Netherlands, Canada, and the United States. Its products also include PEX010, a natural psilocybin drug candidate. It also engages in the production,…
Sign in to search companies, open filing PDFs, fetch uncached SEDAR+ documents, and use the
full company research view.
News 2026-09-10
Rhelion Life Sciences Announces Filament Health is Planning a Stability Program for IBEX011, Its Naturally Derived Ibogaine Drug Candidate
News release - English.pdf
News 2026-09-08
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes Shipment of PEX010 to Australia for University of Melbourne Trial of Psilocybin-Assisted Physiotherapy in Functional Neurological Disorder
News release - English.pdf
News 2026-09-08
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes Shipment of PEX010 to Australia for University of Melbourne Trial of Psilocybin-Assisted Physiotherapy in Functional Neurological Disorder
News release - English.pdf
News 2026-09-03
Rhelion Life Sciences Confirms Further Delivery of Filament Health's PEX010 to Germany's First Psilocybin Compassionate Use Program
News release - English.pdf
Results 2026-08-31
Rhelion Life Sciences Reports First Quarter 2027 Results
News release - English.pdf
Results 2026-08-31
Interim MD&A - English.pdf
Results 2026-08-31
Interim financial statements/report – English.pdf
News 2026-08-27
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Issued New United States Patent, Extending the Broadest Natural Psilocybin Patent Estate
News release - English.pdf
News 2026-08-25
Rhelion Life Sciences Wholly Owned Subsidiary Filament Health Completes Shipment of PEX010 for University of Washington Phase 2a Trial in Cancer-Related Anxiety and Depression
News release - English.pdf
News 2026-08-20
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Letter of Intent with Darmiyan, Inc. to Explore Use of FDA De Novo Authorized BrainSee(R) AI Platform in Early Alzheimer's Disease Trial Design
News release - English.pdf
News 2026-08-14
Rhelion Life Sciences Signs Agreement with University Health Network for Randomized Clinical Trial of Psilocybin in Parkinson's Disease Depression
News release - English.pdf
Results 2026-07-29
Red Light Holland Reports Fiscal 2026 Audited Year-End Results and Provides Update on Rhelion Life Sciences
News release - English.pdf
Results 2026-07-29
Annual MD&A - English.pdf
Results 2026-07-29
Audited annual financial statements – English.pdf
Transactions 2026-07-17 M&A
Red Light Holland Announces Corporate Rebrand to Rhelion Life Sciences Corp
News release - English.pdf
News 2026-07-16
Red Light Holland Announces New Filament Health PEX010 European Research Shipment
News release - English.pdf
News 2026-07-08
Red Light Holland Announces Filament Health's Largest-Ever Manufacturing Run of PEX010, the Standardized and Patented Natural Psilocybin Drug Candidate Trusted Across 80+ Studies Globally, Now Offering the Widest Standardized Dosing Range, from 0.5 mg to 25 mg
News release - English.pdf
News 2026-07-07
Red Light Holland's Subsidiary Filament Health Signs Agreement to Supply PEX010 for Military Veterans PTSD Study
News release - English.pdf
Results 2026-06-18
Red Light Holland Reports Positive Preclinical Study Results for Coca in Weight Gain Prevention Post GLP-1 from Magdalena Biosciences, the Joint Venture Held Through Its Wholly Owned Subsidiary, Filament Health
News release - English.pdf
News 2026-06-08
Red Light Holland's Filament Health Signs Agreement to Supply PEX010 for Study at GHU Paris Psychiatrie & Neurosciences
News release - English.pdf
News 2026-06-04
Red Light Holland Announces Filament Health's PEX010 Drug Candidate, the Standardized and Patented Natural Psilocybin Trusted Across 80+ Studies Globally, Selected by UCSF for Study Probing Preclinical Alzheimer's Markers
News release - English.pdf
News 2026-05-25
Red Light Holland Expands New Zealand Partnership with Allu Therapeutics to Advance Access to Filament Health's GMP-Compliant PEX010 Botanical Psilocybin Drug Candidate
News release - English.pdf
News 2026-05-14
Red Light Holland's Wholly Owned Subsidiary, Filament Health, Advances PEX010 Clinical Footprint with New Canadian Academic Studies in Palliative Care, Bipolar II Depression, and Healthy Adult Mechanism Research
News release - English.pdf
Transactions 2026-05-12 M&A
Red Light Holland Corp. Completes Acquisition of Filament Health Corp. and Announces Intention to Rebrand
Material change report - English.pdf
News 2026-05-08
Red Light Holland Highlights Publication of Randomized Clinical Trial Showing a Single Dose of Psilocybin Reduced Cocaine Use, with Filament Health Holding the Exclusive License to the Data and Intellectual Property
News release - English.pdf
News 2026-05-07
Red Light Holland's Wholly Owned Subsidiary, Filament Health, Expands Distribution of PEX010 Across Canadian and U.S. Research Institutions
News release - English.pdf
Results 2026-05-04
Audited annual financial statements – English.pdf
News 2026-05-04
Red Light Holland Announces Intention to Rebrand
News release - English.pdf
Ownership 2026-05-01
Early warning report.pdf
Transactions 2026-04-30 M&A
Red Light Holland Completes Acquisition of Filament Health, Creating a Global Leader in Psychedelic Drug Development, Commercialization and Distribution
News release - English.pdf
Transactions 2026-04-29 M&A
Red Light Holland Announces Filament Health Obtains Final Order for Proposed Arrangement
News release - English.pdf
Transactions 2026-04-27 M&A
Red Light Holland Announces Filament Health Shareholder Approval of Acquisition
News release - English.pdf
News 2026-04-24
Red Light Holland Showcases Growing Clinical Demand for Filament Health's PEX010 with New and Repeat University Shipments
News release - English.pdf
News 2026-04-20
Red Light Holland Highlights U.S. FDA-Authorized Study Supporting Multi-Session Psilocybin Therapy using Filament Health's Patented PEX010 Botanical Drug Candidate
News release - English.pdf
News 2026-04-07
Red Light Holland Reports Continued Expansion of Filament Health's PEX010 Clinical Network with New License Agreements and Research Shipments
News release - English.pdf
News 2026-04-01
Red Light Holland to Support University of California San Francisco's Global Psychedelic Study Through Filament Health's Clinical Network
News release - English.pdf
Transactions 2026-03-23 M&A
Red Light Holland Announces Filament Health Obtains Interim Order for Proposed Arrangement
News release - English.pdf
News 2026-03-20
Other securityholders documents - English.pdf
News 2026-03-20
Other securityholders documents - English.pdf
News 2026-03-20
Other securityholders documents - English.pdf
News 2026-03-20
Other securityholders documents - English.pdf
News 2026-03-20
Other securityholders documents - English.pdf
News 2026-03-20
Other securityholders documents - English.pdf
News 2026-03-20
Other securityholders documents - English.pdf
News 2026-03-20
Other securityholders documents - English.pdf
News 2026-03-20
Other securityholders documents - English.pdf
News 2026-03-20
Other securityholders documents - English.pdf
News 2026-03-20
Other securityholders documents - English.pdf
News 2026-03-20
Other securityholders documents - English.pdf
News 2026-03-20
Other securityholders documents - English.pdf
News 2026-03-20
Other securityholders documents - English.pdf
News 2026-03-20
Other securityholders documents - English.pdf
News 2026-03-20
Other securityholders documents - English.pdf
News 2026-03-20
Other securityholders documents - English.pdf
News 2026-03-20
Other securityholders documents - English.pdf
News 2026-03-20
Other securityholders documents - English.pdf
News 2026-03-20
Other securityholders documents - English.pdf
News 2026-03-20
Other securityholders documents - English.pdf
Transactions 2026-03-20
Other material contracts - English.pdf
Transactions 2026-03-20 M&A
Red Light Holland Corp. Enters into Arrangement Agreement to Acquire Filament Health Corp.
Material change report - English.pdf
News 2026-03-18
Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate
News release - English.pdf
Transactions 2026-03-10 M&A
Red Light Holland Signs Definitive Agreement with Filament Health to Expand Its Platform for Natural Psychedelic Drug Development and Microdosing Innovation
News release - English.pdf
Results 2026-03-03
Red Light Holland Reports Third Quarter 2026 Results and Provides Corporate Update
News release - English.pdf
Results 2026-03-02 Financials
Interim financial statements/report – English.pdf
Results 2026-03-02 Financials
Interim MD&A - English.pdf
Results 2025-12-01
Red Light Holland Reports Second Quarter 2026 Results and Provides Corporate Update
News release - English.pdf
Results 2025-12-01 Financials
Interim MD&A - English.pdf
Results 2025-12-01 Financials
Interim financial statements/report – English.pdf
News 2025-11-19
Red Light Holland's FDA-Compliant, DEA-Registered Partner Irvine Labs Receives Second, Larger 5kg Psilocybin Shipment via USA Controlled Substances Import Permit
News release - English.pdf
Transactions 2025-11-17 M&A
Red Light Holland Corp. Announces Safeway Expansion and Share Issuances for Debt Settlement and Compensation
Material change report - English.pdf
News 2025-11-11
News release - English.pdf
News 2025-10-14
News release - English.pdf
News 2025-09-30
News release - English.pdf